Therapeutic target tailored chemotherapy
PreclinicalSmall molecule
Therapeutic target tailored chemotherapy is one of 14 small molecule programs targeting Rectal Carcinoma. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Rectal Carcinoma
#DrugCompanyPhaseTrials
1Lanreotide Acetate
AAlbireo, an Ipsen Company
Approved
Adrucil
EElorac, Inc.
Approved
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Eloxatin
TevaPhase 2
Camptosar
PfizerPhase 2
Beyfortus
BeiGenePhase 2
FOLFOX
AstraZenecaPhase 2
FOLFOX4
Eli LillyPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- GGrupo Hospital de Madrid